Glykit-PG 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Glykit-PG 1 Tablet SR is indicated as adjunctive therapy to diet and exercise to achieve better glycemic control in patients inadequately managed with monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly and assess renal and hepatic function before and during treatment. Caution is advised in patients with congestive heart failure, hepatic impairment, or risk factors for lactic acidosis. This combination therapy offers a multifaceted approach to managing hyperglycemia by targeting different pathophysiological defects in type 2 diabetes.